Funding will investigate medical cannabis impact
on arthritis pain and disease management
LEAMINGTON, ON, July 7, 2015 /CNW/ - Aphria Inc.
("Aphria" or the "Company") (TSX-V:APH) has signed a
sponsorship agreement with The Arthritis Society to provide
$100,000 for medical marijuana
research and education programs. The agreement is effective
immediately and extends to March 31,
2016.
With this support, The Arthritis Society will investigate
medical cannabis treatment benefits in arthritis pain and disease
management and develop medical cannabis educational resources for
Canadians living with arthritis. It will also convene a round table
discussion to establish consensus in the arthritis community,
pinpoint top research priorities and identify funding
opportunities.
"Aphria has taken a leadership position in funding high-quality
research and developing much-needed educational tools on the topic
of medical cannabis," said Joanne
Simons, Chief Mission Officer at The Arthritis Society. "Our
collective aim is to help Canadians who live with the chronic pain
of arthritis. By teaming up, we can accelerate our understanding of
medical cannabis as a potential therapeutic option."
"With a growing number of authorized medical marijuana users
accessing cannabis as a treatment option for arthritis, it's
imperative that physicians and patients have access to
evidence-based medical research validating medicinal use and
benefits associated with treatment," stated Vic Neufeld, President and Chief Executive
Officer of Aphria. "The Arthritis Society is the leader in
arthritis research in Canada and
we are thrilled to partner with them to expand the body of clinical
knowledge in this area of treatment for Canadians living with
arthritis."
ABOUT THE ARTHRITIS SOCIETY
The Arthritis Society has
been setting lives in motion for over 65 years. Dedicated to a
vision of living well while creating a future without arthritis,
The Society is Canada's principal
health charity providing education, programs and support to the
over 4.6 million Canadians living with arthritis. Since its
founding in 1948, The Society has been the largest non-government
funder of arthritis research in Canada, investing nearly $190 million in projects that have led to
breakthroughs in the diagnosis, treatment and care of people with
arthritis. The Arthritis Society is accredited under Imagine
Canada's Standards Program. For more information and to make a
donation, visit www.arthritis.ca.
About Aphria
Aphria Inc., a company continued under
the laws of the Province of Ontario and based in Leamington, Ontario, is in the business of
producing, supplying and selling medical marijuana pursuant to the
Marihuana for Medical Purposes Regulations (the "MMPR").
Under the MMPR, Health Canada is responsible for the oversight of
commercial medical marijuana growers such as Aphria. Aphria's
common shares are listed on the TSX Venture Exchange under the
ticker symbol "APH". For more information, visit
www.Aphria.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "intend" and similar
expressions. Forward-looking statements in this news release
include, but are not limited to, statements with respect to
estimated margins and expectations for future growing capacity.
Forward-looking statements necessarily involve known and unknown
risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; marketing costs; loss
of markets; future legislative and regulatory developments
involving medical marijuana; inability to access sufficient capital
from internal and external sources, and/or inability to access
sufficient capital on favourable terms; the medical marijuana
industry in Canada generally,
income tax and regulatory matters; the ability of Aphria to
implement its business strategies; competition; crop failure;
currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not
exhaustive. Readers are further cautioned not to place undue
reliance on forward-looking statements as there can be no assurance
that the plans, intentions or expectations upon which they are
placed will occur. Such information, although considered reasonable
by management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the "Exchange")
nor its Regulation Services Provider (as that term is defined in
the policies of the Exchange) accepts responsibility for the
adequacy or accuracy of this release.
SOURCE Aphria Inc.